Skip to main content
Figure 2 | BMC Health Services Research

Figure 2

From: Survival, healthcare resource use and costs among stage IV ER + breast cancer patients not receiving HER2 targeted therapy: a retrospective analysis of linked SEER-Medicare data

Figure 2

Kaplan-Meier survival analysis for Medicare-eligible stage IV ER + breast cancer patients who did not receive HER2 targeted agents and matched comparison patients. Note: Median survival for the study cohort was 23 months and it was not reached for the comparison cohort during the study period.

Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us